You are here: Industry Insights > BeiGene

News List

BeiGene's Zanubrutinib to Be Approved in China CPhI.CN
May 26, 2020
Zanubrutinib is one of the world's best-selling BTK inhibitor, with sales in 2019 reached 8.08 billion USD.
Novartis signs deal with BeiGene to bolster immunotherapy pipeline Pharmaceutical-Technology
December 22, 2021
Novartis has entered an option, partnership and licence agreement for BeiGene’s anti-cancer therapy, ociperlimab (BGB-A1217), bolstering its research and development works in immuno-oncology.
Novartis Announces Agreement with BeiGene for TIGIT Inhibitor Ociperlimab AmericanPharmaceuticalReview
December 21, 2021
Novartis announced the signing of an option, collaboration and license agreement with BeiGene, Ltd. for ociperlimab (BGB-A1217), expanding the company’s research and development activities in immuno-oncology.
BeiGene Purchases New U.S. Manufacturing and Clinical R&D Center AmericanPharmaceuticalReview
December 02, 2021
BeiGene, Ltd., a global biotechnology company focused on developing and commercializing innovative cancer medicines worldwide, announced today that it has purchased a 42-acre site at the Princeton West Innovation Campus in Hopewell, N.J. to house a new...
The U.S. FDA Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients prnasia
June 15, 2021
Asieris today announced that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with MIBC.
BeiGene’s ovarian cancer drug pamiparib gets conditional approval in China pharmaceutical-technology
May 11, 2021
Discovered by BeiGene researchers, pamiparib inhibits both PARP1 and PARP2. It is being developed as a monotherapy and combination therapy for various solid tumours.
111, Inc. Enters into First-Ever Strategic Partnership with BeiGene prnasia
March 18, 2021
111, Inc., a leading tech-enabled healthcare platform company committed to digitally connecting patients with medicine and healthcare services in China, announced today it has entered into a strategic cooperation agreement with ...
Novartis Expands Oncology Pipeline with In-Licensing of Tislelizumab from BeiGene americanpharmaceuticalreview
January 20, 2021
Novartis has signed a strategic collaboration agreement to in-license tislelizumab from BeiGene in major markets outside of China. Tislelizumab is an anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages.
BeiGene announces collaboration with Novartis to develop and commercialize anti-PD-1 antibody Tislelizumab pharmaceutical-business-review
January 14, 2021
BeiGene announced a collaboration and license agreement with Novartis Pharma AG to develop, manufacture and commercialize BeiGene’s anti-PD-1 antibody tislelizumab in the United States, Canada, Mexico, member countries of the European Union ...
MEI Pharma Announces Expansion of Zandelisib Phase 1b Study americanpharmaceuticalreview
January 11, 2021
MEI Pharma announced that the Phase 1b trial arm exploring zandelisib, an investigational selective phosphatidylinositol 3-kinase (PI3K) delta inhibitor, in combination with zanubrutinib (marketed as BRUKINSA®) ...

Previous page 1 2 3 4 Next page